Management of Chemotherapy Side Effects

Management of Chemotherapy Side Effects

Management of Chemotherapy Side Effects

On this page

General Principles & CINV Intro - Chemo's Cruel Kickbacks

  • Chemotherapy targets rapidly dividing cells: impacts cancer & normal tissues (bone marrow, GIT, hair follicles).
  • Management Pillars:
    • Prophylaxis: Anticipate & prevent predictable toxicities.
    • Dose Modification: Adjust or delay based on severity of side effects.
    • Supportive Care: Hydration, nutrition, growth factors (e.g., G-CSF for neutropenia, EPO for anemia).
    • Symptom Management: Tailored to specific adverse events.
  • CINV (Chemotherapy-Induced Nausea & Vomiting):
    • Common, distressing; significantly impacts patient's quality of life.
    • Key Pathways: Central (chemoreceptor trigger zone - CTZ) & peripheral (gut vagal afferents).
    • Neurotransmitters: Serotonin (5-HT₃), Substance P (NK₁).
    • Types: Acute (<24h), Delayed (>24h), Anticipatory, Breakthrough, Refractory.

⭐ CTCAE (Common Terminology Criteria for Adverse Events) is widely used for grading toxicity and guiding management decisions across clinical trials and practice.

CINV Management - Vomit Veto

Loading diagram…
  • Goal: Prevent CINV by targeting key neurotransmitters (Serotonin, Substance P, Dopamine).
  • Risk Assessment: Crucial for regimen selection (High, Moderate, Low, Minimal emetogenic risk).
  • CINV Phases:
    • Acute: <24 hrs post-chemo.
    • Delayed: >24 hrs post-chemo, up to 5 days.
    • Anticipatory: Before chemo, conditioned response.
  • Core Drug Classes:
    • 5-HT3 Antagonists: (Ondansetron, Granisetron). Palonosetron (long-acting, good for delayed).
    • NK1 Receptor Antagonists: (Aprepitant, Fosaprepitant). Key for HEC; target Substance P.
    • Corticosteroids: (Dexamethasone). Synergistic, broad antiemetic.
    • Olanzapine: Atypical antipsychotic; multi-receptor antagonist for breakthrough/refractory.
    • Benzodiazepines: (Lorazepam). For anticipatory CINV.
Loading diagram…

⭐ NK1 receptor antagonists (e.g., aprepitant) are crucial for preventing delayed CINV with highly emetogenic chemotherapy.

Myelosuppression Mayhem - Blood Cell Blues

Bone marrow suppression by chemo → pancytopenia. Nadir: 7-14 days post-chemo.

  • Neutropenia (↓ Neutrophils): ANC < 1500/mm³ (Severe < 500/mm³).

    • Manage: G-CSF (Filgrastim, Pegfilgrastim). 📌 Mnemonic: "Grandma Fil Needs Pegs for her Low Neutrophils."
    • Prophylaxis: G-CSF if Febrile Neutropenia (FN) risk > 20%.

    ⭐ Febrile neutropenia (ANC < 500/mm³ + fever) is a medical emergency requiring prompt broad-spectrum antibiotics.

  • Anemia (↓ RBCs): Fatigue, pallor.

    • Manage: ESAs (Epoetin, Darbepoetin; Target Hb 10-12 g/dL). Transfusion if Hb < 7-8 g/dL / symptomatic.
  • Thrombocytopenia (↓ Platelets): Platelets < 150,000/mm³ (Severe < 50,000/mm³).

    • Spontaneous bleed risk < 10,000-20,000/mm³.
    • Manage: Platelet transfusions. Oprelvekin (IL-11) - limited use.
Loading diagram…

Other Common Toxicities - Systemic Sucker Punches

  • Cardiotoxicity:
    • Anthracyclines (Doxorubicin): Cumulative; LVEF monitoring. Prevent: Dexrazoxane.
    • Trastuzumab: Reversible LVEF dysfunction.
  • Pulmonary Toxicity:
    • Bleomycin: Pneumonitis/fibrosis (max 400 units).
    • Busulfan: "Busulfan lung".
    • Methotrexate: Acute pneumonitis.
  • Nephrotoxicity:
    • Cisplatin: ATN. Hydration, Amifostine. Monitor GFR.
    • Methotrexate (high dose): Crystalluria. Alkalinize urine, Leucovorin, hydration.
  • Neurotoxicity:
    • Vincristine: Peripheral neuropathy (sensory, motor, autonomic).
    • Cisplatin: Peripheral neuropathy, ototoxicity.
    • Ifosfamide: Encephalopathy. Antidote: Methylene blue.
    • Cytarabine (high dose): Cerebellar toxicity.
  • Hemorrhagic Cystitis: (Cyclophosphamide, Ifosfamide - Acrolein)
    • Prevention: Hydration, MESNA.

⭐ MESNA (Sodium 2-mercaptoethane sulfonate) is crucial for preventing hemorrhagic cystitis with cyclophosphamide/ifosfamide by neutralizing acrolein.

  • Mucositis/Stomatitis: (5-FU, MTX, Doxorubicin)
    • Management: Oral hygiene, cryotherapy, Palifermin.
  • Hand-Foot Syndrome: (Capecitabine, 5-FU, Liposomal Doxorubicin)
    • Management: Dose modification, cooling, emollients, Pyridoxine. oka

High‑Yield Points - ⚡ Biggest Takeaways

  • Nausea/Vomiting: Key drugs: 5-HT3 antagonists (ondansetron), NK1 antagonists (aprepitant).
  • Myelosuppression: Use G-CSF (neutropenia), EPO (anemia), Oprelvekin (thrombocytopenia).
  • Hemorrhagic Cystitis (cyclophosphamide/ifosfamide): Prevent with Mesna and good hydration.
  • Cardiotoxicity (doxorubicin): Dexrazoxane offers protection; monitor LVEF.
  • Mucositis: Palifermin (KGF) promotes healing; good oral hygiene essential.
  • Tumor Lysis Syndrome: Manage with hydration, allopurinol, or rasburicase.
  • Diarrhea (irinotecan, 5-FU): Treat with loperamide; octreotide for severe cases.

Unlock the full lesson and continue reading

Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more

Scan to download app

Scan to download
UNLOCK FREE ACCESS

Practice Questions: Management of Chemotherapy Side Effects

  1. 1. Which drug is primarily used in the treatment of breast cancer?

    • A. Tamoxifen
    • B. Cyproterone
    • C. Testosterone
    • D. Chlorambucil
    Show answer

    Answer: A. Tamoxifen

    Tamoxifen - Tamoxifen is a selective estrogen receptor modulator (SERM) used primarily for estrogen receptor-positive breast cancer, where endocrine therapy is indicated. - By blocking estrogen binding in breast tissue, tamoxifen reduces estrogen-stimulated tumor-cell growth and is therefore the best choice among these options. Cyproterone - Cyproterone is an anti-androgen and progestogen used mainly for prostate cancer, acne, and hirsutism rather than breast cancer. - Its principal action is androgen-receptor blockade with reduced androgen production, which does not target the usual estrogen-driven pathway in breast cancer. Testosterone - Testosterone is an androgen and is not part of the standard primary treatment for breast cancer. - Although high-dose androgens were historically used for palliation in rare metastatic cases, testosterone is not routinely used as breast-cancer therapy. Chlorambucil - Chlorambucil is an alkylating agent used primarily for chronic lymphocytic leukemia and certain lymphomas, not as a primary breast-cancer drug. - By interfering with DNA replication and transcription, it can treat susceptible hematologic malignancies but does not represent standard first-line therapy for breast cancer.

  2. 2. A 16-year-old girl has chronic anemia, pallor, and hepatosplenomegaly without requiring regular transfusions. Her peripheral smear is shown. What is the most likely diagnosis?

    • A. Iron-deficiency anemia
    • B. Megaloblastic anemia
    • C. Thalassemia intermedia
    • D. Autoimmune hemolytic anemia
    Show answer

    Answer: C. Thalassemia intermedia

    Thalassemia intermedia - Thalassemia intermedia causes chronic hemolytic anemia with pallor and hepatosplenomegaly, often without dependence on regular transfusions; elevated HbA2 and HbF support the diagnosis. - The smear shows anisopoikilocytosis with target cells, teardrop cells, and irregularly contracted cells, characteristic of thalassemia-related ineffective erythropoiesis and hemolysis. Autoimmune hemolytic anemia - Autoimmune hemolytic anemia typically produces spherocytes—small, dense red cells lacking central pallor—because of immune-mediated membrane loss. - Although it may cause anemia and splenomegaly, the described anisopoikilocytosis with target cells and teardrop cells is not its predominant morphology. Iron-deficiency anemia - Iron-deficiency anemia causes microcytic, hypochromic red cells, usually with prominent pallor and small cell size rather than extensive target cells. - Uncomplicated iron deficiency generally does not cause hepatosplenomegaly, whereas chronic thalassemia can produce it through hemolysis and extramedullary hematopoiesis. Megaloblastic anemia - Megaloblastic anemia classically shows macrocytosis and hypersegmented neutrophils due to impaired DNA synthesis, findings not described in this smear. - The target-cell-rich poikilocytosis, chronic anemia, hepatosplenomegaly, and lack of regular transfusion dependence favor thalassemia intermedia over megaloblastic anemia.

  3. 3. Which of the following anticancer drugs is least characteristically associated with direct cardiotoxicity?

    • A. Cyclophosphamide
    • B. Doxorubicin
    • C. Cisplatin
    • D. 5-Fluorouracil
    Show answer

    Answer: C. Cisplatin

    Cisplatin - Cisplatin primarily causes nephrotoxicity and neurotoxicity, rather than clinically significant direct cardiac injury. - Although electrolyte disturbances may produce indirect cardiac effects, significant cardiomyopathy or severe arrhythmias are much less common than with the other listed drugs. 5-Fluorouracil - 5-Fluorouracil can cause coronary vasospasm, producing angina or myocardial infarction during or soon after administration. - Its cardiac toxicity may also include ischemic events and arrhythmias, so it is associated with significant cardiotoxicity. Doxorubicin - Doxorubicin is strongly associated with dose-dependent cardiomyopathy, which may progress to irreversible heart failure. - It can also cause acute arrhythmias or a pericarditis-myocarditis syndrome, making it a prominent cardiotoxic anticancer drug. Cyclophosphamide - High-dose cyclophosphamide can cause hemorrhagic myocarditis and rapid-onset cardiac dysfunction, particularly during bone marrow transplantation. - Direct myocardial injury may progress to congestive heart failure, so this drug is associated with significant cardiotoxicity.

  4. 4. A benzodiazepine-naive adult has severe sedation after an isolated diazepam overdose, without seizure disorder or proconvulsant co-ingestion. Which drug specifically reverses the sedation?

    • A. Physostigmine
    • B. Atropine
    • C. Naloxone
    • D. Flumazenil
    Show answer

    Answer: D. Flumazenil

    Flumazenil competitively antagonizes the benzodiazepine-binding site on GABA-A receptors and can reverse sedation in this selected isolated overdose. Supportive airway and ventilatory care remain primary, and flumazenil is generally avoided with benzodiazepine dependence, seizure disorders, or proconvulsant co-ingestion because it can precipitate seizures. Naloxone reverses opioid toxicity, not diazepam toxicity. Physostigmine is used selectively for antimuscarinic toxicity, not diazepam toxicity. Atropine treats muscarinic manifestations of cholinergic poisoning, not diazepam toxicity.

  5. 5. A patient presents with Zollinger-Ellison syndrome due to gastrinoma, experiencing two bleeding ulcers and diarrhoea. Which drug irreversibly inhibits the H+/K+ ATPase in gastric parietal cells?

    • A. Cisapride
    • B. Omeprazole
    • C. Glycopyrrolate
    • D. Cimetidine
    Show answer

    Answer: B. Omeprazole

    Omeprazole - Omeprazole is a proton-pump inhibitor activated in acidic parietal-cell canaliculi; its sulfenamide metabolite covalently and irreversibly inhibits the H+/K+ ATPase. - By blocking the final common pathway of acid secretion, omeprazole provides potent suppression appropriate for refractory ulcers caused by gastrinoma in Zollinger-Ellison syndrome. Cisapride - Cisapride is a 5-HT4 agonist that promotes gastric emptying and increases lower oesophageal sphincter tone; it does not inhibit the parietal-cell proton pump. - Its major distinguishing concern is QT prolongation with risk of torsades de pointes, and it is not an acid-suppressing treatment for Zollinger-Ellison syndrome. Glycopyrrolate - Glycopyrrolate is an antimuscarinic that can reduce gastric secretions, but its antisecretory effect is weaker than direct proton-pump inhibition. - It is primarily used to reduce salivary and respiratory secretions, including as a pre-anaesthetic medication, rather than as definitive therapy for gastrinoma-related acid hypersecretion. Cimetidine - Cimetidine is an H2-receptor antagonist that competitively blocks histamine-mediated acid secretion; it does not irreversibly bind or inhibit the H+/K+ ATPase. - It is less potent than PPIs in severe hypersecretion and is distinguished by cytochrome P450 inhibition and anti-androgenic effects such as gynecomastia.

  6. 6. A patient with a malignancy is undergoing chemotherapy. The platelet counts were reduced after the previous cycle of chemotherapy. Which of the following drugs can be used to treat this patient?

    • A. Amifostine
    • B. Filgrastim
    • C. Oprelvekin
    • D. Erythropoietin
    Show answer

    Answer: C. Oprelvekin

    Oprelvekin - Oprelvekin, a recombinant interleukin-11, stimulates megakaryocyte proliferation and maturation, increasing platelet production. - It is indicated after myelosuppressive chemotherapy to prevent severe thrombocytopenia and reduce the need for platelet transfusions. Erythropoietin - Erythropoietin promotes proliferation and differentiation of erythroid progenitor cells, thereby increasing red blood cell production rather than platelet production. - It is useful for chemotherapy-associated anemia and other causes of reduced erythropoiesis, but it does not treat thrombocytopenia after chemotherapy. Amifostine - Amifostine is a cytoprotective agent and free-radical scavenger that reduces some chemotherapy- and radiation-associated toxicities by protecting normal tissues. - It does not directly stimulate megakaryocyte proliferation or platelet production, so it is not the appropriate treatment for chemotherapy-induced thrombocytopenia. Filgrastim - Filgrastim is a recombinant granulocyte colony-stimulating factor that promotes proliferation and maturation of neutrophil precursors. - It is used to prevent or treat neutropenia and reduce febrile neutropenia, but it does not significantly increase platelet counts.

  7. 7. Resistance to Methotrexate develops due to?

    • A. Rapid proliferation of cancer cells
    • B. Thymidylate kinase deficiency
    • C. Thymidylate synthetase deficiency
    • D. Dihydrofolate reductase excess
    Show answer

    Answer: D. Dihydrofolate reductase excess

    Dihydrofolate reductase excess - Methotrexate inhibits dihydrofolate reductase (DHFR), reducing tetrahydrofolate availability for nucleotide synthesis and DNA replication. - Cancer-cell DHFR overproduction, often through gene amplification or overexpression, provides sufficient target enzyme to overcome inhibition and is a major resistance mechanism. Thymidylate kinase deficiency - Thymidylate kinase deficiency impairs conversion of dTMP toward dTDP and dTTP, disrupting DNA synthesis rather than reducing methotrexate’s inhibition of DHFR. - This deficiency is not a recognized principal mechanism of methotrexate resistance; altered DHFR quantity or function is the more useful distinguishing mechanism. Thymidylate synthetase deficiency - Thymidylate synthetase deficiency would reduce dTMP production and impair DNA synthesis, so it does not allow cells to bypass methotrexate’s action. - Although increased thymidylate synthetase expression can contribute to resistance, deficiency is not the mechanism described here and is less characteristic than DHFR overproduction. Rapid proliferation of cancer cells - Methotrexate is S-phase specific and inhibits DHFR, limiting folate-dependent nucleotide synthesis in dividing cells. - Rapidly proliferating cancer cells are generally more susceptible to effective methotrexate therapy, so proliferation alone does not explain acquired drug resistance.

  8. 8. A 7 – year old boy presented with abdominal pain, vomiting, and oliguria following chemotherapy. His blood pressure is 80/45 mmHg, capillary refill is delayed, and there is no clinical evidence of fluid overload. Investigations reveal hyperuricemia, raised creatinine levels, and hyperkalemia. What is the immediate therapeutic priority?

    • A. Increase urinary urate excretion
    • B. Degrade existing uric acid
    • C. Restore intravascular volume
    • D. Inhibit uric acid synthesis
    Show answer

    Answer: C. Restore intravascular volume

    Restore intravascular volume - This presentation indicates tumor lysis syndrome, with released intracellular contents causing hyperuricemia, hyperkalemia, and acute kidney injury after chemotherapy. - Intravenous hydration is the next step because hypotension and delayed capillary refill indicate intravascular volume depletion. Fluids are guided by intravascular volume, urine output and evidence of overload; rasburicase treats existing hyperuricemia and need not await a completed hydration step. Increase urinary urate excretion - Probenecid increases urinary uric acid excretion by inhibiting tubular reabsorption, but this is unsuitable in established tumor lysis syndrome. - With oliguria and renal dysfunction, probenecid may promote uric acid precipitation within renal tubules and worsen uric acid nephropathy. Degrade existing uric acid - Rasburicase rapidly converts existing uric acid into more soluble allantoin, making it useful for significant hyperuricemia in tumor lysis syndrome. - It can be given concurrently with hydration but does not correct the intravascular volume depletion requiring immediate treatment here. Inhibit uric acid synthesis - Allopurinol inhibits xanthine oxidase and prevents formation of new uric acid, making it mainly useful for prophylaxis before chemotherapy. - In established tumor lysis syndrome, it does not lower existing uric acid rapidly and is less effective than rasburicase for active hyperuricemia.

  9. 9. A 55-year-old woman is undergoing chemotherapy for breast cancer and experiences severe nausea and vomiting. Which antiemetic, recognized for its minimal extrapyramidal side effects, would be appropriate for her condition?

    • A. Ondansetron
    • B. Metoclopramide
    • C. Promethazine
    • D. Prochlorperazine
    Show answer

    Answer: A. Ondansetron

    Ondansetron - Ondansetron is a 5-HT3 receptor antagonist effective against chemotherapy-induced nausea and vomiting through actions on serotonin receptors in the chemoreceptor trigger zone and gastrointestinal tract. - Its favorable adverse-effect profile includes minimal extrapyramidal symptoms, making it appropriate when effective antiemesis is needed without the movement disorders associated with dopamine antagonists. Metoclopramide - Metoclopramide blocks dopamine D2 receptors and can treat nausea, with additional prokinetic effects, but it is not preferred when minimal extrapyramidal toxicity is specifically required. - Higher doses or prolonged use may cause extrapyramidal symptoms, including dystonia and tardive dyskinesia, making it less suitable than ondansetron for chemotherapy-induced vomiting in this patient. Prochlorperazine - Prochlorperazine is a phenothiazine antiemetic that primarily antagonizes dopamine receptors and can reduce nausea, but it is not the best choice when extrapyramidal effects should be minimized. - Its significant risk of acute dystonia and parkinsonism distinguishes it from ondansetron and makes it less suitable for this chemotherapy-associated presentation. Promethazine - Promethazine is a first-generation antihistamine with antiemetic activity, but it is generally less effective for chemotherapy-induced vomiting than 5-HT3 receptor antagonists. - Its prominent sedation and anticholinergic effects make it less suitable as the primary antiemetic here, despite having a lower extrapyramidal risk than dopamine antagonists.

  10. 10. Hand foot syndrome is an adverse effect of what?

    • A. Bleomycin
    • B. Etoposide
    • C. Actinomycin D
    • D. 5-Fluorouracil
    Show answer

    Answer: D. 5-Fluorouracil

    5-Fluorouracil - 5-Fluorouracil commonly causes dose-limiting hand-foot syndrome, also called palmar-plantar erythrodysesthesia, particularly with prolonged or high-dose treatment. - This toxicity produces redness, swelling, pain, and desquamation affecting the palms and soles; capecitabine, its prodrug, can also cause it. Bleomycin - Bleomycin is primarily associated with dose-limiting pulmonary fibrosis, rather than palmar-plantar erythrodysesthesia. - Although hyperpigmentation and mucocutaneous reactions may occur, severe hand-foot syndrome is not a characteristic toxicity of bleomycin. Actinomycin D - Actinomycin D commonly causes myelosuppression, nausea, vomiting, and mucositis, not hand-foot syndrome. - It may cause radiation recall, a distinctive toxicity, but palmar-plantar erythrodysesthesia is not a typical adverse effect. Etoposide - Etoposide is characteristically associated with myelosuppression, including leukopenia and thrombocytopenia, and with alopecia. - Although nonspecific skin reactions can occur, hand-foot syndrome is not a common or characteristic adverse effect of etoposide.

Flashcards: Management of Chemotherapy Side Effects

  1. 1. Procarbazine side effects include _____ and secondary _____. Bonus: Patients should avoid what type of food?

    Show answer

    pulmonary toxicity · leukemia — Tyramine-containing foods (e.g., aged cheese, red wine) due to its MAO inhibitor activity.

  2. 2. Thymidine synthesis inhibitor (MTX, 5-FU, hydroxyurea) use can result in _____-suppression and _____-cytopenia

    Show answer

    myelo · pan

  3. 3. Ifosfamide use can result in _____, with the bladder toxicity arising from the metabolite _____

    Show answer

    hemorrhagic cystitis · acrolein

  4. 4. When injected intravenously, 5FU can be used to treat _____ cancer and _____ cancer

    Show answer

    colon · pancreatic

  5. 5. Cerebellar toxicity is seen with which anti-cancer drug?

    Show answer

    Cytarabine

  6. 6. Radiation recall syndrome is associated with the use of which anti-cancer drugs?

    Show answer

    Anthracyclines

  7. 7. Antineoplastic agents extracted from the _____ plant is: _____ also called Catharanthus roseus

    Show answer

    Periwinkle · Vinca alkaloids

  8. 8. Aldesleukin is a recombinant form of _____ used to treat _____ and _____

    Show answer

    IL-2 · renal cell carcinoma · metastatic melanoma

  9. 9. Cetuximab is a monoclonal antibody against the _____ Receptor most commonly used to treat Stage _____ colorectal cancer

    Show answer

    EGF · IV

  10. 10. _____ is a drug of choice for _____.

    Show answer

    Pemetrexed · mesothelioma

Everything you need for Indian Medical PG prep

Get full Oncourse access with lessons, practice questions, flashcards and AI study tools.

GET STARTED FOR FREE
75% OFFLimited time offer
GET 75% OFF